Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VEL015 open-label extension in mild to moderate Alzheimer's disease
ACTRN12613000170729Phase 2Recruiting
- Sponsor
- Velacor Therapeutics
- Start
- Oct 2012
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sodium selenate in Alzheimer's disease (AD), sponsored by Velacor Therapeutics. Primary endpoints: Longer-term safety and tolerability and Cognitive performance. Started Oct 2012; status: recruiting.
02
Drugs
sodium selenate
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on ACTRN12613000170729.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12613000170729.